| Supplemental data |
The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes.
Condensed Consolidating Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company and |
|
|
|
|
Consolidated |
|
|
Physician |
|
|
Unrestricted |
|
|
Restricted |
|
|
For the nine months ended September 30, 2016 |
|
Total |
|
|
Groups |
|
|
Subsidiaries |
|
|
Subsidiaries(1) |
|
|
Patient service operating revenues |
|
$ |
7,678,053 |
|
|
$ |
287,544 |
|
|
$ |
— |
|
|
$ |
7,390,509 |
|
|
Less: Provision for uncollectible accounts |
|
|
(336,188 |
) |
|
|
(9,178 |
) |
|
|
— |
|
|
|
(327,010 |
) |
|
Net patient service operating revenues |
|
|
7,341,865 |
|
|
|
278,366 |
|
|
|
— |
|
|
|
7,063,499 |
|
|
Capitated revenues |
|
|
2,654,163 |
|
|
|
1,186,001 |
|
|
|
— |
|
|
|
1,468,162 |
|
|
Other revenues |
|
|
1,033,335 |
|
|
|
53,124 |
|
|
|
— |
|
|
|
980,211 |
|
|
Total net operating revenues |
|
|
11,029,363 |
|
|
|
1,517,491 |
|
|
|
— |
|
|
|
9,511,872 |
|
|
Operating expenses |
|
|
9,516,248 |
|
|
|
1,513,569 |
|
|
|
(129 |
) |
|
|
8,002,808 |
|
|
Operating income |
|
|
1,513,115 |
|
|
|
3,922 |
|
|
|
129 |
|
|
|
1,509,064 |
|
|
Debt expense, including refinancing charges |
|
|
(310,359 |
) |
|
|
(9,347 |
) |
|
|
— |
|
|
|
(301,012 |
) |
|
Other income |
|
|
8,067 |
|
|
|
322 |
|
|
|
— |
|
|
|
7,745 |
|
|
Income tax expense |
|
|
366,011 |
|
|
|
10,442 |
|
|
|
52 |
|
|
|
355,517 |
|
|
Net income (loss) |
|
|
844,812 |
|
|
|
(15,545 |
) |
|
|
77 |
|
|
|
860,280 |
|
|
Less: Net income attributable to noncontrolling interests |
|
|
(122,664 |
) |
|
|
— |
|
|
|
— |
|
|
|
(122,664 |
) |
|
Net income (loss) attributable to DaVita Inc. |
|
$ |
722,148 |
|
|
$ |
(15,545 |
) |
|
$ |
77 |
|
|
$ |
737,616 |
|
|
(1) |
After elimination of the unrestricted subsidiaries and the physician groups. |
Condensed Consolidating Statements of Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
Company and |
|
|
|
|
Consolidated |
|
|
Physician |
|
|
Unrestricted |
|
|
Restricted |
|
|
For the nine months ended September 30, 2016 |
|
Total |
|
|
Groups |
|
|
Subsidiaries |
|
|
Subsidiaries(1) |
|
|
Net income (loss) |
|
$ |
844,812 |
|
|
$ |
(15,545 |
) |
|
$ |
77 |
|
|
$ |
860,280 |
|
|
Other comprehensive loss |
|
|
7,807 |
|
|
|
— |
|
|
|
— |
|
|
|
7,807 |
|
|
Total comprehensive income (loss) |
|
|
852,619 |
|
|
|
(15,545 |
) |
|
|
77 |
|
|
|
868,087 |
|
|
Less: comprehensive income attributable to the noncontrolling
interests |
|
|
(122,871 |
) |
|
|
— |
|
|
|
— |
|
|
|
(122,871 |
) |
|
Comprehensive income (loss) attributable to DaVita Inc. |
|
$ |
729,748 |
|
|
$ |
(15,545 |
) |
|
$ |
77 |
|
|
$ |
745,216 |
|
|
(1) |
After elimination of the unrestricted subsidiaries and the physician groups. |
Condensed Consolidating Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company and |
|
|
|
|
Consolidated |
|
|
Physician |
|
|
Unrestricted |
|
|
Restricted |
|
|
As of September 30, 2016 |
|
Total |
|
|
Groups |
|
|
Subsidiaries |
|
|
Subsidiaries(1) |
|
|
Cash and cash equivalents |
|
$ |
913,496 |
|
|
$ |
104,636 |
|
|
$ |
— |
|
|
$ |
808,860 |
|
|
Accounts receivable, net |
|
|
1,850,425 |
|
|
|
195,488 |
|
|
|
— |
|
|
|
1,654,937 |
|
|
Other current assets |
|
|
1,497,438 |
|
|
|
18,419 |
|
|
|
— |
|
|
|
1,479,019 |
|
|
Total current assets |
|
|
4,261,359 |
|
|
|
318,543 |
|
|
|
— |
|
|
|
3,942,816 |
|
|
Property and equipment, net |
|
|
3,044,988 |
|
|
|
1,417 |
|
|
|
— |
|
|
|
3,043,571 |
|
|
Amortizable intangibles, net |
|
|
1,576,157 |
|
|
|
5,141 |
|
|
|
— |
|
|
|
1,571,016 |
|
|
Other long-term assets |
|
|
660,153 |
|
|
|
77,681 |
|
|
|
2,696 |
|
|
|
579,776 |
|
|
Goodwill |
|
|
9,382,996 |
|
|
|
16,405 |
|
|
|
— |
|
|
|
9,366,591 |
|
|
Total assets |
|
$ |
18,925,653 |
|
|
$ |
419,187 |
|
|
$ |
2,696 |
|
|
$ |
18,503,770 |
|
|
Current liabilities |
|
$ |
2,639,469 |
|
|
$ |
229,515 |
|
|
$ |
— |
|
|
$ |
2,409,954 |
|
|
Payables to parent |
|
|
— |
|
|
|
86,335 |
|
|
|
2,696 |
|
|
|
(89,031 |
) |
|
Long-term debt and other long-term liabilities |
|
|
10,195,049 |
|
|
|
50,099 |
|
|
|
— |
|
|
|
10,144,950 |
|
|
Noncontrolling interests subject to put provisions |
|
|
971,744 |
|
|
|
— |
|
|
|
— |
|
|
|
971,744 |
|
|
Total DaVita Inc. shareholders’ equity |
|
|
4,911,746 |
|
|
|
53,238 |
|
|
|
— |
|
|
|
4,858,508 |
|
|
Noncontrolling interests not subject to put provisions |
|
|
207,645 |
|
|
|
— |
|
|
|
— |
|
|
|
207,645 |
|
|
Shareholders’ equity |
|
|
5,119,391 |
|
|
|
53,238 |
|
|
|
— |
|
|
|
5,066,153 |
|
|
Total liabilities and shareholder’s equity |
|
$ |
18,925,653 |
|
|
$ |
419,187 |
|
|
$ |
2,696 |
|
|
$ |
18,503,770 |
|
|
(1) |
After elimination of the unrestricted subsidiaries and the physician groups. |
Condensed Consolidating Statements of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company and |
|
|
|
|
Consolidated |
|
|
Physician |
|
|
Unrestricted |
|
|
Restricted |
|
|
For the nine months ended September 30, 2016 |
|
Total |
|
|
Groups |
|
|
Subsidiaries |
|
|
Subsidiaries(1) |
|
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
844,812 |
|
|
$ |
(15,545 |
) |
|
$ |
77 |
|
|
$ |
860,280 |
|
|
Changes in operating and intercompany assets and liabilities
and non-cash items included in net income |
|
|
636,450 |
|
|
|
152,461 |
|
|
|
(77 |
) |
|
|
484,066 |
|
|
Net cash provided by operating activities |
|
|
1,481,262 |
|
|
|
136,916 |
|
|
|
— |
|
|
|
1,344,346 |
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions of property and equipment |
|
|
(575,243 |
) |
|
|
(592 |
) |
|
|
— |
|
|
|
(574,651 |
) |
|
Acquisitions and divestitures, net |
|
|
(497,331 |
) |
|
|
— |
|
|
|
— |
|
|
|
(497,331 |
) |
|
Proceeds from discontinued operations |
|
|
18,991 |
|
|
|
— |
|
|
|
— |
|
|
|
18,991 |
|
|
Investments and other items |
|
|
(203,659 |
) |
|
|
(2,124 |
) |
|
|
— |
|
|
|
(201,535 |
) |
|
Net cash used in investing activities |
|
|
(1,257,242 |
) |
|
|
(2,716 |
) |
|
|
— |
|
|
|
(1,254,526 |
) |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt |
|
|
(98,724 |
) |
|
|
(4 |
) |
|
|
— |
|
|
|
(98,720 |
) |
|
Intercompany |
|
|
— |
|
|
|
(117,805 |
) |
|
|
— |
|
|
|
117,805 |
|
|
Other items |
|
|
(709,252 |
) |
|
|
— |
|
|
|
— |
|
|
|
(709,252 |
) |
|
Net cash used in by financing activities |
|
|
(807,976 |
) |
|
|
(117,809 |
) |
|
|
— |
|
|
|
(690,167 |
) |
|
Effect of exchange rate changes on cash |
|
|
(1,664 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1,664 |
) |
|
Net decrease in cash |
|
|
(585,620 |
) |
|
|
16,391 |
|
|
|
— |
|
|
|
(602,011 |
) |
|
Cash and cash equivalents at beginning of period |
|
|
1,499,116 |
|
|
|
88,245 |
|
|
|
— |
|
|
|
1,410,871 |
|
|
Cash and cash equivalents at end of period |
|
$ |
913,496 |
|
|
$ |
104,636 |
|
|
$ |
— |
|
|
$ |
808,860 |
|
|
(1) |
After elimination of the unrestricted subsidiaries and the physician groups. |
|